Oncology Drug Development in Practice 2017
 
Program
This page will be updated regularly.

Wednesday, November 22, 2017
09:00 - 09:05Welcome and introduction [More Info]
Speaker: Marinus Lobbezoo, Congress by design, Harmelen, The Netherlands
09:05 - 10:00A1. Cancer and cancer therapeutics [More Info]
Speaker: Rob Berg, INC Research, Amsterdam, The Netherlands
10:00 - 11:15A2. Carcinogenesis & tumor cell biology [More Info]
Speaker: Jos Jonkers, The Netherlands Cancer Institute, Amsterdam, The Netherlands
11:15 - 11:30Break
11:30 - 12:30A3. Oncopathology: Diagnosing cancer [More Info]
Speaker: Paul van Diest, University Medical Center, Utrecht, The Netherlands
12:30 - 13:30Lunch
13:30 - 14:45A4. Essentials of medical oncology [More Info]
Speaker: Jan Vermorken, Antwerp University Hospital, Edegem, Belgium
14:50 - 16:05A5. Essentials of hemato-oncology [More Info]
Speaker: Marie José Kersten, Hematologist, Academic Medical Center, Amsterdam, The Netherlands
16:05 - 16:30Break
16:30 - 17:45A6. Essentials of cancer immunotherapy [More Info]
Speaker: Christian Blank, Netherlands Cancer Institute, Amsterdam The Netherlands
17:45 - 18:00Q&A day 1 overall | Evaluation day 1
18:00 - 19:00Welcome drinks (complimentary drinks in hotel bar)
 
Thursday, November 23, 2017
09:00 - 09:45B1. Drug discovery and preclinical drug testing [More Info]
Speaker: Michel Janicot, JMI ONConsulting, Brussels, Belgium
09:45 - 10:30B2. Preclinical toxicology of anticancer agents (including introduction group exercise) [More Info]
Speaker: Benno Rattel, Amgen, Munich, Germany
10:30Coffee served [More Info]
10:30 - 11:15Group exercise preclinical toxicology | Plenary discussion of group exercise preclinical toxicology
11:15 - 12:25B3. Phase I clinical studies with single agents (including introduction group exercise) [More Info]
Speaker: Ferry Eskens, Erasmus MC, Rotterdam, The Netherlands
12:25 - 13:15Lunch
13:15 - 14:00Group exercise phase I studies | Plenary discussion of group exercise phase I studies
14:00 - 15:00B4. Phase I clinical studies with combinations of agents [More Info]
Speaker: Udai Banerji, The Institute of Cancer Research, London, United Kingdom
15:00 - 15:20Break
15:20 - 16:10B5. Biomarkers in oncology drug development [More Info]
Speaker: Alain van Gool, Radboud University Medical Center, Nijmegen, The Netherlands
16:10 - 17:00B6. Development of companion diagnostics for cancer therapeutics [More Info]
Speaker: Martina Kaufmann, Martina Kaufmann Strategic Consulting, Muellheim, Germany
17:00 - 17:20Q&A with Prof. van Gool and Dr. Kaufmann
17:20 - 17:30Q&A day 2 overall | Evaluation day 2
17:30End of day 2 / Evening free
 
Friday, November 24, 2017
09:00 - 10:00B7. The regulatory environment for anticancer drug development [More Info]
Speaker: Adriaan Fruijtier, CATS Consultants, Dietmannsried, Germany
10:00 - 10:15Break
10:15 - 10:45B8.1. Biostatistical considerations in oncology clinical trials (Part 1): Early- phase trials [More Info]
Speaker: Lucinda Billingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom
10:45 - 11:45B9. Post-registration drug development in oncology [More Info]
Speaker: Eric Hoedemaker, Novartis, The Netherlands
11:45 - 11:55Mini-break
11:55 - 12:40B8.2. Biostatistical considerations in oncology clinical trials (Part 2): Late phase trials [More Info]
Speaker: Lucinda Billingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom
12:40 - 13:30Lunch
13:30 - 15:00B10. Full clinical development of cancer therapeutics (including introduction group exercise) [More Info]
Speaker: Eric van der Putten, Aglaia Biomedical Ventures, Bilthoven, The Netherlands
15:00 - 15:15Break
15:15 - 16:00Group exercise full clinical development | Plenary discussion of group exercise full clinical development
16:00 - 16:30Closing: Take home messages & overall evaluation [More Info]
Speaker: Eric van der Putten, Aglaia Biomedical Ventures, Bilthoven, The Netherlands
16:30Adjourn